A combination of U.S. policies that incentivize offshore investment, along with China’s rapid biotech growth, has created a concerning reality for American families: more of our medicines are being developed, tested, and manufactured in a country with far less rigorous standards than our own.
Preserving American biomedical leadership isn’t just an economic issue; it’s a threat to patient safety at home.